Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 10Leukemia, Lymphocytic, Chronic, B-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Unspecified Adult Solid Tumor, Protocol Specific 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Colorectal Neoplasms 5Waldenstrom Macroglobulinemia 4Rectal Neoplasms 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Extranodal NK-T-Cell 4Lymphoma 4Leukemia, Prolymphocytic 4Leukemia, Myeloid, Acute 4Leukemia 4Hodgkin Disease 4Congenital Abnormalities 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3

Interventions

Pharmacogenomic Testing 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma, Clear Cell × Pharmacogenomic Testing × Clear all
NCT01267955 2026-04-13

Vismodegib in Treating Patients With Advanced Chondrosarcomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
45 enrolled 10 charts
Sarcoma

Chondrosarcoma, Clear Cell, Chondrosarcoma, Chondrosarcoma, Mesenchymal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡